PMatX

PMatX is an innovation lab assembled by M Ventures, HP, and Flex, sited in Yavne, with a mandate to push the frontier of next-generation electronics, biochips, and hardware that intersects with healthcare. It is closer to a corporate-backed deep-tech program than to a conventional venture fund, and the shape of its support reflects that.

The thesis is technically narrow and ambitious. The lab targets profound advancements at the boundary of materials science, microelectronics, and life sciences, with portfolio attention to medical devices, life sciences tools, biochips, sensors, and AI-driven instrumentation. Founders engaging with PMatX are typically working on hardware that requires cleanroom-grade processes, complex supply chains, and the kind of capital intensity that frightens most early-stage investors. The corporate sponsors bring not only capital but materials, manufacturing know-how, and electronics expertise that map directly onto these companies’ actual problems.

Checks run below two hundred and fifty thousand dollars at the Pre-Seed and Seed stages, structured to underwrite the earliest validation work and prepare companies for institutional follow-on. Geography is anchored in Israel, with companies expected to address global markets where the relevant regulatory and customer dynamics are concentrated, primarily the US, Europe, and Asia. The lab is positioned as the first institutional partner for hardware founders who will need additional rounds and serious capital to reach commercial scale, and the corporate-backed structure gives portfolio companies access to validation environments that are otherwise expensive to assemble.

The operating model is closer to a hands-on accelerator than a passive seed investor. Founders work directly with technical staff and corporate partners, with access to facilities and engineering resources that early-stage hardware companies typically cannot afford. The structure rewards founders who want operational depth and are willing to move at the pace of a structured program. It is not a fit for founders looking for a check with limited engagement.

The value-add concentrates in the areas where deep-tech hardware companies most often stall: process engineering, supply chain partnerships, manufacturability, and access to the corporate customers and partners who will eventually validate or buy the product. PMatX is candid about what it is not. It is not a software fund, it is not a wellness fund, and it is not designed for therapeutics or biology-heavy plays without a hardware dimension. For founders building biochips, advanced sensors, or hardware-intensive life sciences tools, the program is one of the few in the region that combines real capital, real corporate access, and real technical infrastructure at the earliest stage. The companies that thrive here are the ones whose technical risk requires substantive partner engagement to retire, and whose founders are comfortable treating the relationship with M Ventures, HP, and Flex as a genuine working partnership rather than a marketing badge.